DrugPatentWatch Database Preview
ULTIVA Drug Profile
Which patents cover Ultiva, and what generic alternatives are available?
Ultiva is a drug marketed by Mylan Institutional and is included in one NDA.
The generic ingredient in ULTIVA is remifentanil hydrochloride. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the remifentanil hydrochloride profile page.
Summary for ULTIVA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 30 |
| Clinical Trials: | 92 |
| Patent Applications: | 2,616 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ULTIVA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ULTIVA |
| DailyMed Link: | ULTIVA at DailyMed |
Pharmacology for ULTIVA
| Drug Class | Opioid Agonist |
| Mechanism of Action | Full Opioid Agonists |
Synonyms for ULTIVA
| 1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester |
| 1-Piperidinepropanoic acid, 4-(methoxycarbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester, monohydrochloride |
| 1-Piperidinepropanoic acid, 4-(methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-, methyl ester |
| 132539-07-2 |
| 132539-07-2 (mono-hydrochloride) |
| 132875-61-7 |
| 132875-61-7 (Parent) |
| 3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester |
| 3-[methoxycarbonyl-4-[(1-oxopropyl)phenylamino]1-piperidine]propanoic acid methyl ester hydrochloride |
| 4-(methoxycarbonyl)-1-(3-methoxy-3-oxopropyl)-4-[phenyl(propanoyl)amino]piperidinium chloride |
| 4-(methoxycarbonyl)-4-((1-oxopropyl)phenylamino)-1-piperidinepropanoic acid methyl ester |
| 4-(Methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-1-piperidinepropanoic Acid Methyl Ester Hydrochloride |
| 4-Carboxy-4-(N-phenylpropionamido)-1-piperidine propionic acid, dimethyl ester, monohydrochloride |
| 4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester |
| 5V444H5WIC |
| AC1L1TZ5 |
| AC1L1TZ8 |
| AC1Q3E9W |
| AC1Q5ZGR |
| API0004789 |
| BIDD:GT0029 |
| C-21265 |
| C08021 |
| C20H28N2O5.HCl |
| CC-34231 |
| CHEBI:32091 |
| CHEBI:8802 |
| CHEMBL1005 |
| CHEMBL1201120 |
| D01177 |
| D08473 |
| DB00899 |
| DEA No. 9739 |
| DTXSID00157826 |
| DTXSID50157614 |
| FT-0631145 |
| FT-0674340 |
| GI 87084B |
| GI 87084X |
| GI-87084B |
| GI87084B |
| GTPL7292 |
| HSDB 8377 |
| L001266 |
| LS-115982 |
| LS-172838 |
| methyl 1-(3-methoxy-3-oxopropyl)-4-(N-phenylpropanamido)piperidine-4-carboxylate |
| methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate |
| methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate hydrochloride |
| methyl 1-(3-methoxy-3-oxopropyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate |
| methyl 1-(3-methoxy-3-oxopropyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate hydrochloride |
| methyl-1-(3-methoxy-3-oxopropyl)-4-[phenyl(propanoyl)amino]piperidin-4-carboxylathydrochlorid |
| P10582JYYK |
| REMIFENTANIL |
| Remifentanil (INN) |
| Remifentanil [INN:BAN] |
| Remifentanil HCl |
| REMIFENTANIL HYDROCHLORIDE |
| Remifentanil hydrochloride (JAN/USAN) |
| Remifentanil hydrochloride [USAN] |
| Remifentanil hydrochloride solution, 100 mug/mL in methanol (as free base), certified reference material |
| Remifentanil hydrochloride, >=97% (HPLC), powder |
| Remifentanil hydrochloride, European Pharmacopoeia (EP) Reference Standard |
| remifentanil monohydrochloride |
| Remifentanyl |
| Remifentanyl Hydrochloride |
| SB17331 |
| SB17332 |
| SCHEMBL36652 |
| SCHEMBL41242 |
| Ultiva (TN) |
| UNII-5V444H5WIC |
| UNII-P10582JYYK |
| ZINC538283 |
| ZTVQQQVZCWLTDF-UHFFFAOYSA-N |
US Patents and Regulatory Information for ULTIVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Institutional | ULTIVA | remifentanil hydrochloride | INJECTABLE;INJECTION | 020630-001 | Jul 12, 1996 | AP | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Mylan Institutional | ULTIVA | remifentanil hydrochloride | INJECTABLE;INJECTION | 020630-002 | Jul 12, 1996 | AP | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Mylan Institutional | ULTIVA | remifentanil hydrochloride | INJECTABLE;INJECTION | 020630-003 | Jul 12, 1996 | AP | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for ULTIVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mylan Institutional | ULTIVA | remifentanil hydrochloride | INJECTABLE;INJECTION | 020630-003 | Jul 12, 1996 | ➤ Sign Up | ➤ Sign Up |
| Mylan Institutional | ULTIVA | remifentanil hydrochloride | INJECTABLE;INJECTION | 020630-003 | Jul 12, 1996 | ➤ Sign Up | ➤ Sign Up |
| Mylan Institutional | ULTIVA | remifentanil hydrochloride | INJECTABLE;INJECTION | 020630-001 | Jul 12, 1996 | ➤ Sign Up | ➤ Sign Up |
| Mylan Institutional | ULTIVA | remifentanil hydrochloride | INJECTABLE;INJECTION | 020630-002 | Jul 12, 1996 | ➤ Sign Up | ➤ Sign Up |
| Mylan Institutional | ULTIVA | remifentanil hydrochloride | INJECTABLE;INJECTION | 020630-001 | Jul 12, 1996 | ➤ Sign Up | ➤ Sign Up |
| Mylan Institutional | ULTIVA | remifentanil hydrochloride | INJECTABLE;INJECTION | 020630-003 | Jul 12, 1996 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for ULTIVA
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 1 mg/vial, 2 mg/vial and 5 mg/vial | ➤ Subscribe | ➤ Sign Up |
